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Conclusion: We experienced excellent short term local 
control and low incidence of complication for acoustic 
schwannomas undergoing frameless SRS treatment. Our data 
compare favorably with the literature. Additional follow-up 
will be necessary to evaluate long term results of treatment. 
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Purpose or Objective: A patient with malignant melanoma 
and 4 visible lesions on a gadolinium (Gd)-enhanced T1 MRI 
scan of the brain was reported at the tumor board as having 
at least 7 probable metastases on the basis of the matching 
susceptibility-weighted imaging (SWI). SWI detects cerebral 
microbleeds and may therefore be more sensitive than Gd-T1 
MRI in the detection of small haemorrhagic metastases and 
prediction of future sites of intra-cranial relapse. Our aim 
was to explore the potential usefulness of SWI in 1) the 
selection for radiosurgery and 2) the follow-up of patients 
with brain metastases from malignant melanoma and renal 
cell carcinoma (RCC). 
 
Material and Methods: At the time of referral for 
radiosurgery, a 3-D Gd-T1 MRI was evaluated at the neuro-
oncology multidisciplinary tumor board to determine the 
number of brain metastases. We retrospectively analysed the 
synchronous SWI sequence to explore any difference in the 
number of detectable lesions and hence putative metastases. 
Subsequent enhanced T1-weighted MRIs were evaluated for 
new metastases at the site of SWI abnormalities. 
 
Results: T1 MRI scans detected 16 metastases in a sample of 
11 patients with melanoma and RCC who were treated with 
primary or postoperative linear accelerator-based 
radiosurgery in our center. 25 regions of signal change were 
detectable on the matching SWI sequences. The scans were 
reviewed by a board-certified neuro-radiologist who 
confirmed that the 9 additional SWI lesions were non-
metatastic. To date, none of the additional lesions have 
developed into enhancing brain metastases. Indeed, 
additional SWI changes on postoperative imaging resolved 
completely on subsequent imaging. Thus the 16 SWI changes 
with metastatic features correlated perfectly with the 16 
metastases on Gd-T1 MRI. (Figure 1) 
 
 
 
Conclusion: SWI sensitively detects blood products in primary 
and secondary brain tumours, but also in veins, vascular 
malformations and postop-operative bleeding and 
calcification. An expert neuro-radiology opinion in the 
context of the tumour board is essential for the accurate 
interpretation of SWI to avoid “overdiagnosis” of metastases, 
particularly in the post-operative setting. Occasionally 
however, additional lesions that are highly suspicious for 
metastases may be detected on SWI. The sensitivity and 
specificity of SWI for metastases should be determined in a 
larger cohort as it may assist patient selection for 
radiosurgery in borderline cases. 
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Purpose or Objective: SEGA is a WHO grade I glioma that is 
almost exclusively seen in young patients with tuberous 
sclerosis complex (TSC). Despite the benign histology, SEGA 
can be severely symptomatic as it typically arises 
intraventricularly and can cause obstructive hydrocephalus. 
The current standard treatment of SEGA includes surgical 
resection and chemotherapy, the m-TOR inhibitor 
everolimus. Based on expert opinion, there is an 
international consensus that radiotherapy should not be used 
in the treatment of SEGA.  
Here, we present a case of a patient with TSC, with 
inoperable bilateral ventricular SEGA. Years long before the 
availability of everolimus or its approval for treating SEGA, 
we treated this patient exclusively with radiotherapy.  
 
Material and Methods: With stereotactic fractionated 
radiotherapy, a dose of 60 Gy in 30 fractions of 2 Gy, was 
delivered on the GTV. The patient was afterwards followed 
up with MR imaging. We did volumetric assessment of tumour 
size on each follow up MRI and tracked the changes in tumour 
size after radiotherapy.  
We performed an extensive literature study to verify the 
sources of the consensus against radiotherapy in treatment of 
SEGA. 
 
Results: The patient tolerated the treatment very well. No 
acute or chronic side effects were seen. A follow up over a 
period of 8 years, using MR imaging, showed about 70% 
decrease in tumour volume.  
We found that the advice against radiotherapy appears to be 
based on very little, if any, evidence. 
 
Conclusion: Radiotherapy can be a potential useful tool in 
the treatment of SEGA. The slow but progressive response of 
SEGA to radiotherapy resembles what is seen in other benign 
brain tumors e.g. meningioma. Radiotherapy has been 
discarded prematurely as a therapeutic option for SEGA and 
could be very well used to consolidate effect of everolimus. 
Prospective registration of patients and treatment outcome is 
needed to enhance knowledge. 
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Purpose or Objective: The role of radiotherapy in the 
treatment of intraspinal tumors constitutes a paradigm, 
justified by tolerance of spinal cord. Advances in SBRT 
(Stereotactic Body Radiation Therapy) as robotic and image-
guided treatments have revolutionized in this group. The aim 
of this study is to analyze our preliminary experience treating 
intraspinal tumors using robotic SBRT. 
 
Material and Methods: Clinical and dosimetric data on 19 
patients between 2011 and 2015 were reviewed, patients 
with lesions in spinal canal including intramedullary and 
intradural extramedullary were selected solely. All patients 
were treated with robotic SBRT image-guided in real time 
(Cyberknife). 
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Results: A total of 26 lesions were included in the analysis. 
Median follow-up was 14 months (3-41 months). Thirteen 
were metastatic lesions with histology as breast cancer, 
medulloblastoma, adenoid cystic among others. Response 
rates were: 31% complete response and partial response / 
stable at 69%. 13 benign lesions highlighting arteriovenous 
malformations, neurofibroma and melanocytoma. Response 
rates for this group: complete response in 8%, partial 
response / stable at 92%. During the follow-up time only 5 
patients had relapsed 100% to distance. Median overall 
average dose was 21 Gy (14-35 Gy), the median was three 
fractions (1-5 Fractions), median prescription isodose was 
83% (77-88%) with an average coverage of 97.27% (93.13-
100%). There were no data as myelopathy ≥ Grade II 
associated to treatment in the whole cohort, the most 
common symptom after treatment was fatigue. 
 
Conclusion: The treatment of intraspinal tumors with image-
guided robotic SBRT, has proven to be a feasible,safe and 
effective option for treatment, where treatment options are 
scarce. In our experience, the data are encouraging and 
comparable with those reported by other authors. 
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Purpose or Objective: Adult brain stem gliomas are rare 
accounting for 1-2% of adult gliomas. They are heterogeneous 
with varying clinical and radiological presentation. Prognosis 
remains poor because of limited surgical options and 
radiotherapy still remains the main treatment option. We 
report our clinical experience of treating brain stem glioma. 
 
Material and Methods: A Retrospective review was made to 
analyze the clinical presentation, diagnosis, treatment 
outcome and survival in adult brain stem glioma patients 
treated at Shaukat Khanum Memorial Cancer Hospital Lahore. 
Between July 2007 and August 2014. 
 
Results: 46 patients were identified from Hospital record 
system. Diagnosis was mostly based on radiological findings 
with MRI brain and biopsy was done only in 11 patients. 98% 
of the patients were treated with radiotherapy as a first line 
treatment on presentation and 1 patient was kept under 
close surveillance which was treated on progression. Median 
radiotherapy dose used ranged between (20-60Gy) with a 
median dose of 51Gy. Age of the patients ranged from 18 to 
72 years (median 33 years) with a Male to female ratio of 
3:1.Median follow up duration was 9 months (range 1-72). 
Radiological response was seen in 65% (13% partial & 52% 
stable) of the patients. The median overall survival (OS) for 
entire cohort was 10 months. One and two year OS rates 
were 46% and 25% respectively. Radiological Low grade 
Glioma showed a median survival of 11.5 months and was 
found to be 9.5 months for High grade Glioma. (p=0.864). 
ECOG Performance status 0,1,2 and 3 showed median survival 
of 13.6, 11.5, 6 and 3 months respectively (p=.02) 
 
Conclusion: Survival still remains dismal despite high 
radiotherapy dose. The role of cytogenetics and 
chemotherapy should be explored to improve outcome. 
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Purpose or Objective: 
Background: Brain metastases (BM) are the most common 
CNS malignancies. They represent an important cause of 
morbidity and mortality in cancer patients. In the literature, 
few studies have evaluated the efficacy of stereotactic 
reirradiation (SRT) for recurrent brain metastases as a 
salvage treatment option after a prior radiotherapy.  
Objectives: This study reports the clinical outcome and 
tolerance of repeat irradiation with CyberKnife robotic 
stereotactic delivery in patients with recurrent brain 
metastases and a history of prior cerebral radiotherapy. 
Overall survival (OS), intracranial progression-free survival 
(PFS), local control (LC) and prognostic factors associated 
with overall survival (OS) were evaluated. 
 
Material and Methods: Patients treated from April 2010 to 
January 2015 for recurrent brain metastases were 
retrospectively included. Univariate and multivariable 
analyses included age, performance status, recursive 
partitioning analysis (RPA), extratracranial disease control, 
and time from initial RT to SRT. The prior radiotherapy was 
WBRT for 27 patients (dose from 30 Gy to 45 Gy) , 
radiosurgery with Gamma knife for 8 patient (dose from 18 
Gy to 25 Gy) and hypo fractionated stereotactic radiotherapy 
in 2 patients. The tumor size ranged from 1to 4 cm (median 2 
cm).  
 
Results: In total, 37 Patients with 53 recurrent brain 
metastases and a median age of 58 years (Range 33-82 years) 
were included. The median number of metastases per patient 
was 2 (range 1-4), treated with a median dose of 21 Gy 
(range 10-36) per treatment, with a median of 3 fractions 
(range 1-9) per patient. The median follow-up was 10,1 
months (range 1-19 months). The OS rate from the SRT was 
57,2%( IC 95%: 34.6-74.6). Two (5%) of 12 deaths were from 
neurologic causes. The median PFS was 5.8 months (IC 95%: 
3.6-9.3). On multivariate analysis, controlled extracranial 
disease is correlated with better overall survival 31% (IC 95%: 
15-50; p= 0,005). Adverse radiation events developed was 
acceptable.  
 
 
